Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12611454-B2

Patent

Publication Date

2026-04-28

Expiration Date


Abstract

An active or inactivated recombinant vaccine against COVID-19 is described that comprises a Newcastle disease viral vector and a pharmaceutically acceptable carrier, adjuvant and/or excipient, characterized in that the viral vector is a virus capable of generating a cellular immune response that has a SARS-COV-2 exogenous nucleotide sequence inserted.

Core Innovation

The invention provides a recombinant Newcastle disease virus (NDV) comprising an NDV viral vector and an exogenous nucleotide sequence encoding antigenic sites of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). The exogenous nucleotide sequence comprises a spike (S) protein ectodomain of SARS-COV-2 fused to a transmembrane domain and a cytoplasmic domain of an NDV fusion (F) protein. The polybasic cleavage site of the S ectodomain is mutated to an alanine and specific amino acids corresponding to positions 817, 892, 899, 942, 986 and 987 of the ectodomain of SEQ ID NO:11 are mutated to prolines.

The recombinant NDV vector and the antigenic sites are described as stable after at least 3 consecutive passages in chicken embryo. The vector is further characterized as an NDV viral vector comprising SEQ ID NO:6 or SEQ ID NO:14 carrying the SARS-COV-2 antigenic sites.

The invention also provides a coronavirus disease 2019 (COVID-19) vaccine comprising the recombinant NDV and a pharmaceutically acceptable carrier, adjuvant and/or excipient. The vaccine is defined with the same spike ectodomain fusion architecture and the same cleavage-site mutation to alanine and proline substitutions corresponding to the specified positions.

Claims Coverage

Two independent claims are present: one directed to a recombinant NDV construct and one directed to a COVID-19 vaccine formulation comprising that construct plus pharmaceutically acceptable components. Across the independent claims, the main inventive features concern a specific NDV vector, an exogenous SARS-COV-2 spike ectodomain fused to an NDV F transmembrane/cytoplasmic domain, defined spike mutations, and stability after at least 3 consecutive passages in chicken embryo.

Recombinant NDV with engineered SARS-COV-2 spike ectodomain fusion and defined stability

A recombinant Newcastle disease virus (NDV) comprising a NDV viral vector comprising SEQ ID NO:6 or SEQ ID NO:14 and an exogenous nucleotide sequence encoding for antigenic sites of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), wherein the exogenous nucleotide sequence comprises an ectodomain of a spike (S) protein of SARS-COV-2 fused to a transmembrane domain and a cytoplasmic domain of a NDV fusion (F) protein, wherein the polybasic cleavage site of the ectodomain of the S protein is mutated to an alanine and amino acids that correspond to amino acids 817, 892, 899, 942, 986 and 987 of the ectodomain of the S protein of SEQ ID NO:11 are mutated to prolines, whereby the NDV viral vector and the antigenic sites are stable after at least 3 consecutive passages in chicken embryo.

COVID-19 vaccine with recombinant NDV and formulation components

A coronavirus disease 2019 (COVID-19) vaccine comprising a recombinant Newcastle disease virus (NDV) comprising an NDV viral vector comprising SEQ ID NO:6 or SEQ ID NO:14 and an exogenous nucleotide sequence encoding for antigenic sites of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), wherein the exogenous nucleotide sequence comprises an ectodomain of a spike (S) protein of SARS-COV-2 fused to a transmembrane domain and a cytoplasmic domain of a NDV fusion (F) protein, wherein the polybasic cleavage site of the ectodomain of the S protein is mutated to an alanine and amino acids that correspond to amino acids 817, 892, 899, 942, 986 and 987 of the ectodomain of the S protein of SEQ ID NO:11 are mutated to prolines, whereby the NDV viral vector and the antigenic sites are stable after at least 3 consecutive passages in chicken embryo, and a pharmaceutically acceptable carrier, adjuvant and/or excipient.

The independent claims cover a recombinant NDV vector carrying a specifically fused SARS-COV-2 spike ectodomain antigenic-site sequence with defined cleavage-site and proline mutations, and a COVID-19 vaccine formulation comprising that recombinant NDV and pharmaceutically acceptable carrier/adjuvant/excipient.

Stated Advantages

NDV viral vector and the SARS-COV-2 antigenic sites are stable after at least 3 consecutive passages in chicken embryo.

Documented Applications

No documented applications found

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.